Work

Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial

Year: 2025

Type: article

Source: JAAD International

DOI: 10.1016/j.jdin.2025.09.015

Authors: Ravi Ramessur, Zelma C. Chiesa Fuxench, Daniel Shin, Jennifer B. Mason, Anabel C. Mason, Maryte Papadopoulos, Bruna Galvao de Oliveira Wafae, Megan H. Noe, Joel M. Gelfand

Institutions: University of Pennsylvania, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Harvard University

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,575

Funder: Bristol-Myers Squibb

OpenAlex ID: W4414978942

FWCI:

Cites: 5

Cited by:

Related to: 10